People who have lost weight with injectable drugs can keep it off with a daily Orforglipron tablet. This is according to a new clinical trial published on 12 May.
Orforglipron: a new approach to weight control
Pros. message The Guardian, an international team of researchers conducted a trial that showed that taking Orforglipron daily helps people maintain weight loss after completing a course of injectable GLP-1 medications. Participants in the clinical trial who switched from injections to Orforglipron, They were able to avoid the typical return of extra pounds.
How Orforglipron works
Orforglipron is an oral medicine belonging to the class of GLP-1 agonists. These medicines mimic the action of the hormone that regulates appetite and blood sugar levels. Until now, most weight loss drugs such as semaglutide have been used as injections. The new tablet formulation can make life much easier for patients seeking to maintain a healthy weight without the need for regular injections.
The researchers note that after stopping injection therapy, many people quickly regain the weight they lost. However, this effect was much less pronounced in the Orforglipron group. The participants in the experiment were able to maintain their weight loss results for a long time.
Implications for patients and medicine
The discovery of a tablet alternative to injectables could have a significant impact on the approach to obesity treatment and overweight. Switching to Orforglipron not only helps to maintain the results achieved, but also simplifies the medication regimen, which is especially important for people with chronic health problems.
Experts point to the drug's potential for widespread use in the future. However, further studies are needed to assess the long-term safety and efficacy of Orforglipron in different patient groups.
Why it matters
The introduction of a tablet GLP-1 drug opens up new opportunities for people struggling with obesity. Orforglipron may change the way weight loss is maintained after injection therapy, reducing the risk of weight gain and improving the quality of life for patients. It could also influence strategies to combat the global obesity epidemic.
